Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid President Donald Trump's tariff policies.

Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems. The news comes on the heels of an announced $700 million investment in North Carolina.

The committee awarded a grant to Genentech, a Roche subsidiary, to open a 420-worker, drug-manufacturing plant in the fast-growing part of southwestern Wake County. Roche pledged to create these jobs between 2028 and 2032 at an average yearly salary of at least $119,800.

Roche will invest up to $550 million in its Indianapolis diagnostics site by 2030 to expand production of its continuous glucose monitoring systems. The Indianapolis location serves as the headquarters for Roche Diagnostics and currently produces 5.

The move is part of Roche’s previously announced plan to invest $50 billion in pharmaceuticals and diagnostics over the next five years in the United States. Roche Diagnostics, with its North America unit based in Indianapolis, is a maker of instruments to help physicians and laboratories test for a wide range of patient conditions.

AS Monaco and Roche Bobois, a French brand specializing in high-end furnishings and decoration with an international reputation, are delighted to announce the extension of their partnership for a

President Donald Trump's executive order mandates drugmakers to lower prices to match those in affluent nations, threatening Roche's $50 billion U.S. investment plan. While the policy may be tough to implement,

The National Health Insurance Authority has signed an expanded Memorandum of Understanding with a leading multinational healthcare company, Roche, to enhance access to affordable cancer care and treatment.